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Summary
 Background The bioeffect of a physical dose depends on the nature of the tissue, fractiona-
tion scheme, dose rate and treatment time. Certainly, experienced radiothera-
pists are convinced of the existence of patient-to-patient variability in normal tis-
sue response to radiotherapy for malignant tumours. The absorbed dose needs 
to be translated into a bioeffect dose, which takes into account treatment varia-
bles and the radiobiological characteristics of the relevant tissue. Various bioef-
fect models such as NSD, CRE, TDF and BED have been proposed to predict the 
biological effect of radiotherapy treatments.
 Aim This study was aimed at deriving tolerance bioeffect dose values for normal tis-
sue complication rate.
 Materials/Methods Compiled clinical data of time dose fractionation schedules and incidence of ery-
thema, desquamation and telangiectasia were used for the present analysis.
 Results For erythema and desquamation the radiation dose varied from 23.9 to 55.1Gy 
in 04 to 50 fractions (dose per fraction 1.1 to 7.3Gy) in 11 to 40 days. For tel-
angiectasia (score ≥1 at 3 years) the radiation dose varied from 25.8 to 55.1Gy in 
04 to 50 fractions (dose per fraction 1.1 to 7.3Gy) in 11 to 40 days. For telangiecta-
sia (score ≥2 at 5 years) the radiation dose varied from 25.8 to 63.0Gy in 04 to 
50 fractions (dose per fraction 1.1 to 7.3Gy) in 11 to 68 days. For telangiectasia 
(score ≥1, ≥2, ≥3, ≥4 at 10 years) the radiation dose varied from 25.8 to 63.0Gy 
in 04 to 35 fractions (dose per fraction 1.7 to 7.3Gy) in 22 to 68 days. TDF and 
LQF values for erythema, desquamation and telangiectasia were evaluated with 
a/b values of 7.5Gy, 11.2Gy and 2.8Gy respectively. TDF and LQF had a statisti-
cally signiﬁ cant correlation with probability of erythema, desquamation and tel-
angiectasia (p<0.001).
 Conclusions TDF and LQF values should be limited to 60 and 86Gy in order to limit the prob-
ability of telangiectasia.
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BACKGROUND
The aim of the radiation oncologist is uncom-
plicated loco-regional control of cancer by radi-
ation therapy. To achieve this goal, precise knowl-
edge of tumoricidal dose and tolerance doses of 
various normal tissues is most helpful. The mon-
umental work of Rubin and Cassarett [1] was a 
major step in this direction. From nearly a cen-
tury of clinical experience, a number of empir-
ical rules have been obtained to aid radiothera-
pists in achieving higher therapeutic gain. The 
bioeffect of a physical dose depends on the na-
ture of the tissue, fractionation scheme, dose rate 
and treatment time. The absorbed dose needs to 
be translated into a bioeffect dose, which takes 
into account treatment variables and the radio-
biological characteristics of the relevant tissue. 
Various bioeffect models have been proposed 
to predict the biological effect of radiotherapy 
treatments.
From time to time, various concepts such as the 
nominal standard dose (NSD) [2], cumulative 
radiation effect (CRE) [3,4] and time dose frac-
tionation (TDF) factors [5,6] have been put for-
ward to test the equivalence of treatment sched-
ules. The NSD formula, despite its limitations, 
provided radiotherapists with an important ini-
tial step in understanding the effects of fraction-
ation on the tolerance of skin and connective tis-
sue. The TDF formula allowed addition of the 
TDF values for different portions of a course of 
radiation treatment. These concepts were wide-
ly accepted in spite of their empirical nature. 
However, doubts have been raised periodically 
as to the accuracy of prediction of early and late 
effects of normal tissues. Now the linear quad-
ratic (LQ) model is being used increasingly to 
predict the biological effect of fractionated radi-
otherapy using different parameters for a partic-
ular tissue, such as a/b, μ, K and Td [7–13]. Dale 
[8] proposed extrapolated response dose (ERD) 
equations for external beam therapy, intracavi-
tary brachytherapy and interstitial brachythera-
py. Within the context of the LQ model the pa-
rameter which quantiﬁ es the overall biological 
effect on a given tissue is the biologically effec-
tive dose (BED), which is obtained by applying 
repopulation correction to ERD [12].
Certainly, experienced radiotherapists are con-
vinced of the existence of patient-to-patient vari-
ability in normal tissue response to radiotherapy 
for malignant tumours. However, there are pitfalls 
in the clinical impressions of the individual differ-
ences, even if the prescribed dose regimens are 
exactly the same. The inter-individual variation 
in response is most easily seen for acute effects 
in skin and mucosa as the patients are frequent-
ly investigated during and shortly after the treat-
ment course. There is now evidence that dose-re-
sponse relationships for normal tissue and organ 
effects are steep; in general, they are steeper for 
late effects than for early effects.
This study was undertaken to apply TDF and LQF 
to clinical data of skin erythema, desquamation 
and telangiectasia in order to arrive at tolerance 
values for an acceptable level of probability of 
complication rate.
MATERIALS AND METHODS
Clinical data of time dose fractionation schedules 
and incidence of erythema, desquamation and 
telangiectasia was used for the present analysis 
[21,22]. For erythema data radiation dose varied 
from 23.9 to 55.1Gy and the maximum number 
of patients (43.3%) was in the dose range of 40.1 
to 50.0Gy. The number of fractions varied from 
04 to 50 and the maximum number of patients 
(35.4%) was in the range of 04 to 10 fractions. 
The dose per fraction varied from 1.1 to 7.3Gy 
and the maximum number of patients (38.5%) 
was in the dose per fraction range of 1.1 to 2.0Gy. 
Treatment time varied from 11 to 40 days and 
the maximum number of patients (50.3%) was 
in the treatment days range of 21 to 30 days. For 
desquamation data radiation dose varied from 
23.9 to 55.1Gy and the maximum number of 
patients (41.9%) was in the dose range of 40.1 
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to 50.0Gy. The number of fractions varied from 
04 to 50 and the maximum number of patients 
(35.6%) was in the range of 04 to 10 fractions. 
The dose per fraction varied from 1.1 to 7.3Gy 
and the maximum number of patients (39.1%) 
was in the dose per fraction range of 1.1 to 2.0Gy. 
Treatment time varied from 11 to 40 days and the 
maximum number of patients (50.4%) was in the 
treatment days range of 21 to 30 days.
For telangiectasia data (score ≥1 at 3 years) radia-
tion dose varied from 25.8 to 55.1Gy and the max-
imum number of patients (47.9%) was in the dose 
range of 40.1 to 50.0Gy. The number of fractions 
varied from 04 to 50 and the maximum number 
of patients (36.2%) was in the range of 21 to 30 
fractions. The dose per fraction varied from 1.1 
to 7.3Gy and the maximum number of patients 
(38.2%) was in the dose per fraction range of 1.1 
to 2.0Gy. Treatment time varied from 11 to 40 days 
and the maximum number of patients (41.6%) 
was in the treatment days range of 21 to 30 days. 
For telangiectasia data (score ≥2 at 5 years) ra-
diation dose varied from 25.8 to 63Gy and the 
maximum number of patients (36.3%) was in 
the dose range of 40.1 to 50.0Gy. The number of 
fractions varied from 04 to 50 and the maximum 
number of patients (33.2%) was in the range of 
04 to 10 fractions. The dose per fraction varied 
from 1.1 to 7.3Gy and the maximum number 
of patients (33.8%) was in the dose per fraction 
range of 1.1 to 2.0Gy. Treatment time varied from 
11 to 68 days and the maximum number of pa-
tients (40.9%) was in the treatment days range 
of 21 to 30 days.
For telangiectasia data (score ≥1 at 10 years) radi-
ation dose varied from 25.8 to 63Gy and the maxi-
mum number of patients (31.3%) was in the dose 
range of 25.8 to 30Gy. The number of fractions 
varied from 04 to 35 and the maximum number 
of patients (40.2%) was in the range of 04 to 10 
fractions. The dose per fraction varied from 1.7 
to 7.3Gy and the maximum number of patients 
(37.5%) was in the dose per fraction range of 3.1 
to 4.0Gy. Treatment time varied from 22 to 68 days 
and the maximum number of patients (43.2%) 
was in the treatment days range of 31 to 40 days. 
For telangiectasia data (score ≥2 at 10 years) ra-
diation dose varied from 25.8 to 63Gy and the 
maximum number of patients (31.9%) was in 
the dose range of 25.8 to 30.0Gy. The number of 
fractions varied from 04 to 35 and the maximum 
number of patients (40.7%) was in the range of 
04 to 10 fractions. The dose per fraction varied 
from 1.7 to 7.3Gy and the maximum number 
of patients (37.9%) was in the dose per fraction 
range of 3.1 to 4.0Gy. Treatment time varied from 
22 to 68 days and the maximum number of pa-
tients (43.6%) was in the treatment days range 
of 31 to 40 days.
For telangiectasia data (score ≥3 at 10 years) radi-
ation dose varied from 25.8 to 63Gy and the maxi-
mum number of patients (30.5%) was in the dose 
range of 25.8 to 30.0Gy. The number of fractions 
varied from 04 to 35 and the maximum number 
of patients (39.5%) was in the range of 04 to 10 
fractions. The dose per fraction varied from 1.7 
to 7.3Gy and the maximum number of patients 
(38.2%) was in the dose per fraction range of 3.1 
to 4.0Gy. Treatment time varied from 22 to 68 days 
and the maximum number of patients (45.5%) 
was in the treatment days range of 37 to 40 days. 
For telangiectasia data (score ≥4 at 10 years) radi-
ation dose varied from 25.8 to 63Gy and the maxi-
mum number of patients (30.2%) was in the dose 
range of 25.8 to 30.0Gy. The number of fractions 
varied from 04 to 35 and the maximum number 
of patients (39.6%) was in the range of 04 to 10 
fractions. The dose per fraction varied from 1.7 
to 7.3Gy and the maximum number of patients 
(37.3%) was in the dose per fraction range of 
3.1 to 4.0Gy. Treatment time varied from 22 to 
68 days and the maximum number of patients 
(45.3%) was in the treatment days range of 31 to 
40 days. TDF and LQF values for erythema, desq-
uamation and telangiectasia were evaluated with 
the following equations with a/b values of 7.5Gy, 
11.2Gy and 2.8Gy respectively [11,21,22].
Erythema
TDF = 1.19 d1.54 n x–0.17
LQF = 1.34 Nd [1+(d/7.5)] x–0.17
Desquamation
TDF = 1.19 d1.54 n x–0.17
LQF = 1.34 Nd [1+(d/11.2)] x–0.17
Telangiectasia
TDF = 0.90 d1.79 n x–0.16
LQF = 1.23 Nd [1+(d/2.8)] x–0.16
RESULTS
Data regarding classiﬁ cation of patients as per 
TDF and LQF for erythema are given in Table 1. 
TDF values ranged from 44 to 85 and the maxi-
mum number of patients (47.7%) had TDF var-
ying from 71 to 80. LQF values ranged from 
41 to 97Gy and the maximum number of pa-
tients (34.8%) had LQF varying from 61 to 70Gy. 
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Correlation of TDF and LQF with probability of 
erythema is indicated in Table 2. Both TDF and 
LQF had statistically signiﬁ cant correlation with 
probability of erythema. Probability of erythema 
increased signiﬁ cantly beyond a TDF of 63 and 
LQF of 48Gy.
Data regarding classiﬁ cation of patients as per 
TDF and LQF for desquamation are given in 
Table 3. TDF values ranged from 44 to 85 and 
the maximum number of patients (47.6%) had 
TDF ranging from 71 to 80. LQF values ranged 
from 38 to 93Gy and the maximum number of 
patients (24.6%) had LQF values ranging from 
41 to 50Gy. Correlation of TDF and LQF with 
probability of desquamation is given in Table 4. 
Both TDF and LQF indicated a statistically sig-
niﬁ cant correlation with probability of desqua-
mation (p<0.001). Probability of desquamation 
increased signiﬁ cantly beyond a TDF value of 68 
and LQF value of 59Gy.
Classiﬁ cation of patients as per TDF and LQF 
for telangiectasia (score ≥1 at 3 years) is shown 
in Table 5. TDF values ranged from 46 to 98 and 
the maximum number of patients (34.2%) had 
TDF values ranged from 58 to 107Gy and the 
maximum number of patients (44.3%) had LQF 
values ranging from 91 to 100 Gy. Correlation 
of TDF and LQF with probability of telangiecta-
sia (score ≥1 at 3 years) is given in Table 6. TDF 
and LQF had a statistically signiﬁ cant relation-
ship with probability of telangiectasia (p<0.001). 
Probability of telangiectasia increased signiﬁ -
cantly beyond a TDF value of 60 and LQF val-
ue of 87Gy.
Criteria Range Number Percentage
TDF
44–50 41 5.4
51–60 120 15.9
61–70 129 17.1
71–80 360 47.7
81–85 105 13.9
ERD (Gy)
41–50 130 17.2
51–60 155 20.5
61–70 263 34.8
71–80 147 19.5
81–90 49 6.5
91–97 11 1.5
Table 1. Classifi cation of patients as TDF and ERD (Erythema 
data).
Criteria Range No/Total Percentage p value
TDF
44–63  37/196 18.9 <0.001
64–76  204/394 51.8
77–85  130/165 78.8
LQF (Gy)
41–48  26/130 20.0 <0.001
49–78  264/529 49.9
79–97  81/96 84.4
Table 2. Correlation of TDF and LQF with probability of erythema.
Criteria Range Number Percentage
TDF
44–50 43 5.6
51–60 131 17.2
61–70 174 22.8
71–80 364 47.6
81–85 95 12.4
ERD (Gy)
38–40 14 1.8
41–50 188 24.6
51–60 207 27.1
61–70 179 23.4
71–80 165 21.6
81–90 0 0.0
91–93 11 1.4
Table 3. Classifi cation of patients as per TDF and ERD (Desquamation 
data).
Criteria Range No/Total Percentage p value
TDF
44–68  6/237 2.5 <0.001
69–78  79/400 19.8
79–85  50/127 39.4
LQF (Gy)
38–59  16/369 4.3 <0.001
60–63  28/136 20.6
64–93  91/259 35.1
Table 4. Correlation of TDF and LQF with probability of 
desquamation.
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Classiﬁ cation of patients as per TDF and LQF 
for relangiectasia (score ≥2 at 5 years) is given 
in Table 7. TDF values ranged from 46 to 98 and 
the maximum number of patients (32.5%) had 
TDF values ranging from 71 to 80. LQF values 
ranged from 58 to 114 and the maximum number 
of patients (34.5%) had LQF ranging from 91 to 
100Gy. Correlation of TDF and LQF with prob-
ability of telangiectasia (score ≥2 at 5 years) is 
shown in Table 8. TDF and LQF indicated a sta-
tistically signiﬁ cant relationship with probabili-
ty of telangiectasia (p<0.001). Probability of tel-
angiectasia increased signiﬁ cantly beyond TDF 
value of 60 and LQF value of 87Gy.
Classiﬁ cation of patients as per TDF and LQF for 
telangiectasia (score ≥1 at 10 years) is shown in 
Table 9. TDF values varied from 47 to 97 and the 
maximum number of patients (29.7%) had TDF 
values ranging from 81 to 90. LQF values ranged 
from 67 to 114Gy and the maximum number of 
patients (37.5%) had LQF values ranging from 
91 to 100Gy. Correlation of TDF and LQF with 
probability of telangiectasia (score ≥1 at 10 years) 
is shown in Table 10. TDF and LQF indicated a 
statistically signiﬁ cant relationship with probabil-
ity of telangiectasia (p<0.001). Probability of te-
langiectasia increased signiﬁ cantly beyond TDF 
value of 71 and LQF value of 89Gy.
Classiﬁ cation of patients as per TDF and LQF for 
telangiectasia (score ≥2 at 10 years) is given in Table 
11. TDF values ranged from 47 to 97 and the max-
imum number of patients (29.8%) had TDF val-
Criteria Range Number Percentage
TDF
 46–50 35 6.3
 51–60 26 4.7
 61–70 190 34.2
 71–80 179 32.3
 81–90 32 5.8
 91–98 93 16.8
ERD (Gy)
 58–60 24 4.3
 61–70 11 20.0
 71–80 35 6.3
 81–90 159 28.7
 91–100 246 44.3
 101–107 80 14.4
Table 5. Classifi cation of patients as per TDF and ERD (Telangiectasia 
score 1 at 3 year data).
Criteria Range No/Total Percentage p value
TDF
 46–60  14/61 23.0 <0.001
 61–85  169/393 43.0
 86–96  76/101 75.2
LQF (Gy)
 58–87  50/179 27.9 <0.001
 88–91  60/114 52.6
 92–107  149/262 56.9
Table 6. Correlation of TDF and LQF with probability of telangiectasia 
score 1 at 3 year.
Criteria Range Number Percentage
TDF
 46–50 31 5.9
 51–60 22 4.2
 61–70 134 25.3
 71–80 172 32.5
 81–90 58 10.9
 91–98 113 21.3
ERD (Gy)
 58–60 21 4.0
 61–70 10 1.9
 71–80 34 6.4
 81–90 149 28.1
 91–100 183 34.5
 101–110 78 14.7
 111–114 53 10.4
Table 7. Classifi cation of patients as per TDF and ERD (Telangiectasia 
score 2 at 5 year data).
Criteria Range No/Total Percentage p value
TDF
 46–60  9/53 17.0 <0.001
 61–73  68/193 35.2
 74–98  183/284 64.4
LQF (Gy)
 58–87  39/166 23.5 <0.001
 88–94  69/131 52.7
 95–114  152/233 65.2
Table 8. Correlation of TDF and LQF with probability of telangiectasia 
score 2 at 5 year.
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ues ranging from 71 to 80. LQF values ranged from 
67 to 114 and the maximum number of patients 
(37.5%) had LQF values ranging from 91 to 100Gy. 
Correlation of TDF and LQF with probability of te-
langiectasia (score ≥2 at 10 years) is shown in Table 
12. TDF and LQF had a statistically signiﬁ cant cor-
relation with probability of telangiectasia (p<0.001). 
Probability of telangiectasia increased beyond TDF 
values of 71 and LQF value of 86Gy.
Classiﬁ cation of patients as per TDF and ERD for 
talengiectasia (score ≥3 at 10 years) is given in 
Table 13. TDF values ranged from 47 to 97 and 
the maximum number of patients (30.0%) had 
TDF values ranging from 71 to 80. LQF values 
ranged from 67 to 114 and the maximum number 
of patients (36.9%) had LQF values ranging from 
91 to 100Gy. Correlation of TDF and LQF with 
probability of telangiectasia (score ≥3 at 10 years) 
is given in Table 14. TDF and LQF indicated a sta-
tistically signiﬁ cant relationship with probability 
Criteria Range Number Percentage
TDF
 47–50 8 3.1
 51–60 21 8.1
 61–70 23 8.9
 71–80 75 29.0
 81–90 77 29.7
 91–97 55 21.2
ERD (Gy)
 67–70 8 3.1
 71–80 31 12.0
 81–90 65 25.1
 91–100 97 37.5
 101–110 0 0.0
 111–114 58 22.4
Table 9. Classifi cation of patients as per TDF and ERD (Telangiectasia 
score 1 at 10 year data).
Criteria Range No/Total Percentage p value
TDF  47–71  42/75 56.0 <0.001
 72–97  169/184 91.8
LQF (Gy)  67–89  67/104 64.4 <0.001
 90–114  144/155 92.9
Table 10. Correlation of TDF and LQF with probability of 
telangiectasia score 1 at 10 year.
Criteria Range Number Percentage
TDF
 47–50 8 3.2
 51–60 20 8.1
 61–70 30 12.1
 71–80 74 29.8
 81–90 71 28.6
 91–97 53 21.4
ERD (Gy)
 67–70 8 3.2
 71–80 31 12.6
 81–90 63 25.5
 91–100 93 37.5
 101–110 0 0.0
 111–114 53 21.4
Table 11. Classification of patients as per TDF and ERD 
(Telangiectasia score 2 at 10 year data).
Criteria Range No/Total Percentage p value
TDF  47–71  24/72 33.3 <0.001
 72–97  143/176 81.3
LQF (Gy)  67–86  36/81 44.4 <0.001
 87–114  131/167 78.4
Table 12. Correlation of TDF and LQF with probability of 
telangiectasia score 2 at 10 year.
Criteria Range Number Percentage
TDF
 47–50 8 3.4
 51–60 21 9.0
 61–70 22 9.4
 71–80 70 30.0
 81–90 64 27.5
 91–97 48 20.6
ERD (Gy)
 67–70 8 3.4
 71–80 29 12.5
 81–90 62 26.6
 91–100 86 36.9
 101–110 0 0.0
 111–114 48 20.6
Table 13. Classification of patients as per TDF and ERD 
(Telangiectasia score 3 at 10 year data).
Original Paper Rep Pract Oncol Radiother, 2007; 12(1): 19-29
24
of telangiectasia (p<0.001). Probability of tel-
angiectasia increased signiﬁ cantly beyond TDF 
value of 60 and LQF value of 86Gy.
Classiﬁ cation of patients as per TDF and LQF for 
telangiectasia (score ≥4 at 10 years) is shown in 
Table 15. TDF values ranged from 47 to 97 and 
the maximum number of patients (34.7%) had 
TDF ranging from 71 to 80. LQF values ranged 
from 67 to 114 and the maximum number of pa-
tients (36.0%) had LQF values ranging from 91 
to 100Gy. Correlation of TDF and LQF with prob-
ability of telangiectasia (score ≥4 at 10 years) is 
given in Table 16. TDF and LQF indicated a sta-
tistically signiﬁ cant relationship with probabili-
ty of telangiectasia (p<0.001). Probability of tel-
angiectasia increased signiﬁ cantly beyond TDF 
value of 60 and LQF value of 86Gy.
DISCUSSION
Bioeffect dose takes into account treatment var-
iables and the radiobiological characteristics of 
the relevant tissue. Certainly, experienced ra-
diotherapists are convinced of the existence of 
patient-to-patient variability in normal tissue re-
sponse to radiotherapy for malignant tumours. 
To establish the inﬂ uence on normal tissues of 
various prognostic factors requires that a sufﬁ -
cient number of patients be treated with a wide 
range of fractionation regimens and that sufﬁ -
cient numbers develop complications. The pool-
ing of clinical data from a large multi-institution-
al experience characterized by a wide diversity of 
dose fractionation patterns, extending over dec-
ades, yields a sufﬁ cient number of patients and 
a wide enough range of variables for correlation 
of the probability of severe late sequelae. Despite 
the limitations of retrospective analyses they pro-
vide useful radiobiological parameters of normal 
tissue responses.
Hamilton et al. [14] studied the underpredic-
tion of human skin erythema at low doses per 
fraction by the linear quadratic model. The lin-
ear quadratic model signiﬁ cantly underpredict-
ed peak erythema values at doses less than 1.5Gy 
per fraction. This suggests that either the con-
ventional linear quadratic model does not apply 
for low doses per fraction in human skin or that 
erythema is not exclusively initiated by radiation 
damage to the basal layer. The data are potential-
ly explained by an induced repair model.
Simonen et al. [15] studied the contribution of in-
ﬂ ammatory processes in erythema observed in the 
skin of humans in two prospective trials that eval-
uated potential effects of topical indomethacin 
(1%) and hydrocortisone (1%) applied before 
and during radiotherapy. Drugs were compared 
Criteria Range No/Total Percentage p value
TDF
 47–60  0/29 0.0 <0.001
 61–78  24/92 26.1
 79–97  80/112 71.4
LQF (Gy)
 67–86  12/79 15.1 <0.001
 87–97  29/62 46.8
 98–114  63/92 68.5
Table 14. Correlation of TDF and LQF with probability of 
telangiectasia score 3 at 10 year.
Criteria Range Number Percentage
TDF
 47–50 8 3.6
 51–60 21 9.0
 61–70 21 9.0
 71–80 78 34.7
 81–90 61 27.1
 91–97 46 20.5
ERD (Gy)
 67–70 8 3.6
 71–80 27 12.1
 81–90 62 27.6
 91–100 81 36.0
 101–110 0 0.0
 111–114 47 20.9
Table 15. Classification of patients as per TDF and ERD 
(Telangiectasia score 4 at 10 year data).
Criteria Range No/Total Percentage p value
TDF
 47–60  0/29 0.0 <0.001
 61–78  5/89 5.6
 79–97  55/107 51.4
LQF (Gy)
 67–86  4/97 4.1 <0.001
 87–97  10/38 26.3
 98–114  46/90 51.1
Table 16. Correlation of TDF and LQF with probability of 
telangiectasia score 4 at 10 year.
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for erythema induced by 20Gy in four fractions 
(n=26, 6MV) in trial I and effects of topical hydro-
cortisone (1%) applied before and during radi-
otherapy and no medication were compared for 
erythema induced by 1, 3, 5 and 7Gy in ﬁ ve frac-
tions (n=21, 120kV) in trial II, respectively. The 
authors concluded that inﬂ ammatory responses 
may play a role in the mediation of the erythema-
tous response to radiation in human skin.
Denham et al. [16] determined the inﬂ uence of 
changes in dose rate over the range 0.8–240Gy/h 
on acute oropharyngeal mucosal reactions in hu-
man subjects, and estimated the values of the 
important parameters that inﬂ uence these re-
actions. Sixty-one patients requiring radiother-
apy to palliate incurable head and neck cancer 
were treated on a telecaesium unit, using oppos-
ing lateral portals to total midline doses, varying 
between 30 and 42Gy in 10 daily fractions over 2 
weeks, at dose rates of 0.8, 1.8, 3.0 and 240Gy/h 
according to a central composite study design. 
The severity and time course of reactions were 
charted at least twice weekly for each patient, 
using the EORTC/RTOG acute mucosal reac-
tion grading system. Duration of reaction at 
each grade was observed to provide a more sen-
sitive reﬂ ection of effect than the proportion of 
patients reaching any particular reaction grade. 
Analysis of duration by direct and indirect meth-
ods suggest a/b ratios in the range 7–10Gy and 
half-time (t1/2) values in the range 0.27–0.5h, if 
mono-exponential repair kinetics are assumed. 
The t1/2 values are short and raise the question 
as to whether the repair kinetics of this tissue 
are well described by a mono-exponential func-
tion. Further prospective studies involving mul-
tiple daily fraction treatment regimes delivered 
at high dose rate, in which interfraction inter-
val is deliberately varied, are needed to ﬁ nd out 
whether the parameters derived from this project 
are applicable to fractionated treatment courses 
at high dose rate.
Denham et al. [17] studied mucosal regeneration 
during radiotherapy. Mucosal reactions were ob-
served in 100 patients undergoing conventionally 
fractionated treatment at 2Gy/day over 7 weeks 
and 88 receiving accelerated treatment at 1.8Gy 
twice daily over 31/2 weeks in the Trans-Tasman 
Radiation Oncology Group head and neck can-
cer trials. Similar observations in 61 patients treat-
ed palliatively using ten 3.0–4.2Gy fractions over 
2 weeks are compared. The study suggests that 
the timing and magnitude of the regenerative re-
sponse vary between sites and individuals but are 
linked to the amount of epithelial cellular deple-
tion occurring during treatment.
Turesson et al. [18] studied the predictive value 
of skin telangiectasia for late radiation effects in 
different normal tissues. Comprehensive radio-
pathological studies have shown that vasculoco-
nnective tissue is an important common target 
for late effects in various organs. Scoring of skin 
telangiectasia was used as a clinical assay of late 
tissue effects after different dose schedules. All 
studies were done prospectively with standardized 
skin area, ﬁ eld size and radiation quality. The pa-
tients were scored regularly up to 10 years. The 
analysis shows that: 1) ED10/5yr and ED50/5yr for 
5×4.0Gy/wk is 50Gy and 65Gy, respectively, for 
distinct telangiectasia; 2) The latent period, con-
cerning both a certain frequency and degree of 
reaction, varies exponentially with dose level; 3) 
The latent period for 50% of patients to obtain a 
certain score, LP50, is correlated to that for 10%, 
LP10, with LP50/LP10=2.2±0.2 (S.D.). This correla-
tion is independent of score, total dose, and frac-
tionation; 4) Isoeffective doses for 5×2.0Gy/wk 
and 2×4.0Gy/wk, determined from the dose-re-
sponse curves, resulted in repair factors exp N 
between 0.31 and 0.32 and a/b ratios between 
2.9 and 3.1Gy and determined from the dose-la-
tency curves in exp N between 0.30 and 0.32 and 
a/b ratio between 3.4 and 2.9Gy. In conclusion, 
frequent and careful follow-up with registration 
of normal tissue reactions, until at least 10% of 
the patients have obtained that prescribed ef-
fect, is predictive for the further progression of 
the late effects. The fractionation characteristics 
for telangiectasia agree well with those for ani-
mal experimental morphological and function-
al endpoints for late effects in different organs 
and support the relevance of telangiectasia as a 
model for predicting late effects.
Bentzen et al. [19] analysed the methodological 
problems in estimating radiobiological parame-
ters from clinical data. A number of biological, 
dosimetric and statistical problems encountered 
in the determination of a/b ratios and the rel-
ative biological efﬁ ciency (RBE) of high energy 
electrons are discussed. As a practical example, 
the dose-response relationships for severe ery-
thema and subcutaneous ﬁ brosis are discussed 
in two series of patients treated with post-mastec-
tomy irradiation with electrons and photons in 
two fractionation schedules. Because of a differ-
ent dose per fraction in the electron and photon 
ﬁ elds, determination of RBE requires a fraction 
size correction. This is performed using that a/b 
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formalism. This analysis suggests a high energy 
electron RBE for severe erythema of 0.93 (95% 
conﬁ dence limits 0.89 and 0.96) and for subcu-
taneous ﬁ brosis of 0.84 (95% conﬁ dence limits 
0.77 and 0.92).
Baltas et al. [20] analyzed the late effects data using 
dose-response models for human skin telangiecta-
sia. The clinical data for skin telangiectasia from 
previous prospective studies at the Radiotherapy 
Department in Gothenborg are reanalyzed using 
two dose response models – the general formu-
lation of the well known linear-quadratic (LQ) 
and NSD isoeffect models. The results show that 
within the interval of the number of fractions 
used, 10–35 fractions, the NSD model gives pre-
dictions comparable to those of the LQ model. 
For number of fractions smaller than 5, a high 
discrepancy occurs between the two models, the 
NSD model predicting higher values of the iso-
effective total dose. Based on the estimated dose 
response curves, considering the telangiectasia as 
the decisive late tissue effect, the requirement for 
the combined uncertainty in the dose delivery is 
estimated at between 3 and 4.5%.
Turesson et al. [21] studied repair capacity and 
kinetics of human skin during fractionated radio-
therapy after 3 and 5 years of follow-up. The clin-
ical assay consisted of breast cancer patients irra-
diated postoperatively to the internal mammary 
nodes from unilateral or bilateral ﬁ elds exposed 
to various dose schedules. Unexpectedly, there 
was no signiﬁ cant time factor during radiotherapy 
courses up to 6 weeks for erythema and desqua-
mation, but the repair capacity was changed after 
4 weeks for both endpoints, and a/b increased 
to between 18.3 and 34.5Gy. The repair capacity 
for late telangiectasia differed signiﬁ cantly from 
that for erythema and desquamation, with a/b 
values as 2.8 and 4.3Gy. There was a signiﬁ cant 
time factor for talangiectasia with characteristic 
doubling time of about 16 days, when an expo-
nential function for time was used. The time fac-
tor and the relatively long half-time for repair for 
late effects have important implications for mul-
tiple-fraction-per-day treatment, and imply that 
interfraction intervals of 4h or less, as commonly 
used, will be insufﬁ cient. Instead, intervals of 6h 
or longer are recommended. Using accelerated 
fractionation with a signiﬁ cant reduction in over-
all treatment time, a dose reduction is still neces-
sary to take into account the time factor for late 
effects. Further data are necessary for more reli-
able estimates of the time factor and the repair 
kinetics for both acute and late effects.
Turesson et al. [22] analysed skin telangiectasia 
and head and neck morbidity and studied the 
characteristics of dose-response relationships 
for late radiation effects. One, 2 and 5 fractions 
per week and 3 to 4 dose levels per schedule 
were used for this study. The following parame-
ters were determined for each schedule and the 
equivalent single dose-response curves for each 
endpoint using probit analysis: ED50, the absolute 
steepness, measured as the probit width, K; the 
relative steepness, K/ED50; and the normalized 
effect gradient, g50. The a/b value was found to 
be independent of the degree of telangiectasia 
used as endpoint. The absolute steepness of the 
dose-incidence curve increased with increasing 
dose per fraction and was correlated to the de-
gree of damage. The relative steepness was inde-
pendent of the dose per fraction when the dose-
response curve was generated by a ﬁ xed dose per 
fraction, and was less than if generated by a ﬁ xed 
number of fractionations. The relative steepness 
increased with higher degree of damage. The 
highest steepness determined for relangiecta-
sia score ≥4 (partially conﬂ uent or more) at 10 
years corresponded to K=0.8Gy, K/ED50=5%, 
g50=7 and D0=0.7Gy. The dose response charac-
teristics found for late skin telangiectasia score 
≥2 to ≥4 were consistent with those determined 
for necrosis and fatal complications 5 years after 
radiotherapy for head and neck tumours.
Maciejewski et al. [23] studied the acute and late 
effects on normal tissue responses with dose frac-
tionation and regeneration in radiotherapy for 
cancer of the oral cavity and oropharynx. The 
severity of acute responses correlated with dose 
intensity. The incidence of severe late responses 
increased with increase in dose per fraction and 
was characterized by a low a/b ratio. Severe late 
responses were signiﬁ cantly associated with se-
vere acute responses independently of dose per 
fraction and total dose, and were also ameliorat-
ed slightly by protraction of treatment time, sug-
gesting that some late effects were, at least part-
ly, a consequence of acute injury. Probability of 
local tumour control correlated with severity of 
acute response, suggesting that excessive protrac-
tion of overall treatment time to minimize acute 
toxicity may compromise local control of the tu-
mour. There was no demonstrable correlation 
between the volume of tissue irradiated and the 
severity of acute or late responses.
Hopewell et al. [24] studied reappraisal of the 
importance of the overall treatment and its ef-
fects on radiosensitization and incomplete repair 
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with dose fractionation on early and late respons-
es in pig skin. A simple approach to a time fac-
tor could not be used to calculate iso-effect dos-
es for acute reactions in pig skin when treatment 
time was increased from ≤16 days to 28–39 days. 
This was due to the opposing effects of radiosen-
sitization and repopulation when the cell cycle 
time of epidermal basal cells was shortened. For 
late dermal necrosis in pig skin, repair of suble-
thal damage was not completed in 24 hours. This 
ﬁ nding has a signiﬁ cant effect on the interpreta-
tion of the results of fractionation studies using 
this late endpoint. Many of the fractionation ef-
fects reported for acute and late damage to pig 
skin would appear to be in excellent agreement 
with those for human skin.
Bentzen et al. [25] studied the relationship be-
tween early and late normal tissue injury after 
postmastectomy radiotherapy. Patients who de-
veloped moist desquamation had a statistical-
ly signiﬁ cantly increased risk of developing tel-
angiectasia after a speciﬁ c course of radiotherapy. 
As an example the estimated incidence of severe 
telangiectasia after 44Gy in 22 fractions increas-
es from 27% to 49% in patients who developed 
grade ≥2 moist desquamation as an early radi-
ation reaction. A reanalysis of the Aarhus data 
with telangiectasia as the endpoint gave an a/b 
ratio at 2.8Gy and a relative biological effective-
ness (RBE) of high energy electrons relative to 
8MV photons at 0.89. Patients’ age or the oc-
currence of severe erythema did not predispose 
to telangiectasia. A similar predisposition after 
moist desquamation was not seen for subcuta-
neous ﬁ brosis.
Turesson et al. [26] analysed the prognostic fac-
tors for acute and late skin reactions in 402 breast 
cancer patients. Multivariate analyses were per-
formed with peak reﬂ ectance erythema and peak 
acute reaction score as endpoints for the acute re-
actions, and with progression rate of telangiecta-
sia as well as telangiectasia score as endpoints for 
the late reactions. Twenty patient- and treatment-
related factors were tested, such as age, meno-
pausal status, haemoglobin level, serum calcium, 
smoking habits, hypothyroidism, diabetes, hy-
pertension, blood pressure, cardiovascular and 
autoimmune disease, the inﬂ uence of hormone 
therapy and chemotherapy, pretreatment reﬂ ect-
ance value, acute skin reactions, radiation quality, 
individual dose, bilateral ﬁ elds, and the total ef-
fect (TE) for the dose schedule applied. The TE 
was a strong prognostic factor for all endpoints. 
The only independent prognostic factors found 
for the progression of skin telangiectasia and te-
langiectasia score except for TE were the indi-
vidual dose and acute skin reactions.
CONCLUSIONS
We analysed the clinical data of patients for ery-
thema, desquamation and telangiectasia on the 
basis of bioeffect models. TDF and LQF had a 
statistically signiﬁ cant correlation with probabil-
ity of erythema, desquamation and telangiecta-
sia. TDF and LQF values should be limited to 60 
and 86Gy in order to limit the probability of te-
langiectasia.
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